Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data

Figure 1 Cetuximab induces autophagy and upregulates 4E-BP1 expression and autophagy enhances anti-cancer effect of cetuximab in colon cancer. A: CACO-2 cell viability measured using MTT assay. Cell viability was significantly inhibited in a time- and dose-dependent manner by cetuximab. B: Cetuximab induced formation of autophagosomes. Autophagosomes in CACO-2 cells treated by cetuximab or not were examined by fluorescence microscopy. More autophagosomes were found in CACO-2 cells after treatment with cetuximab. C: Western blot analysis showing that cetuximab induced autophagy. (a) CACO-2 cells were either untreated or treated with cetuximab and Baf, and Baf inhibited autophagy-related protein degradation. Microtubule-associated protein 1A/B-light chain 3 (LC3)-II/LC3-I was increased, and P62 was decreased when treated with cetuximab, and both LC3 and P62 were increased when treated with cetuximab and Baf compared to treatment with cetuximab alone. (b and c) Cetuximab induced autophagy in a concentration and time dependent manner. With time and increasing concentration, the expression of LC3 increased, and P62 declined. (d) CACO-2 cells were treated with cetuximab for 48 h, and the expression of 4E-binding protein 1 was increased as the concentration of cetuximab increased. D: Effect of autophagy on cetuximab inhibition of cell proliferation. We added PBS, cetuximab, cetuximab + Beclin1-siRNA, and cetuximab + NC-siRNA separately, and the concentration of cetuximab was 78 µg/mL; then, cells were treated for 72 h. The results confirmed that autophagy enhanced cetuximab inhibition of cell proliferation in CACO-2 cells. LC3: Microtubule-associated protein 1A/B-light chain 3; 4E-BP1: 4E-binding protein 1.